Nemaura Medical Inc (FRA:N18A)
€ 0.115 0 (0%) Market Cap: 2.11 Mil Enterprise Value: 19.96 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100

Nemaura Medical Inc Positive Results from Head-to-Head Study with Major CGM Call Transcript

May 10, 2020 / NTS GMT
Dave Gentry
RedChip Companies, Inc. - Analyst

Back to Chowdhury. Thanks for being with us today.

Faz Chowdhury
Nemaura Medical Inc. - CEO & Chairman of the Board

That's my pleasure.

Questions & Answers

Dave Gentry
RedChip Companies, Inc. - Analyst

And you recently announced a head-to-head study with one of the major incumbents in the continuous glucose monitoring space. What can you tell us about the study?

Faz Chowdhury
Nemaura Medical Inc. - CEO & Chairman of the Board

Yes. So let me give you some background as to why we decided to start these studies. We've had discussions with a number of health insurers. Because, of course, our target is to get product reimbursement. Now when we look at the existing CGM, whether it's Dexcom or the Abbott, you've got CGMs that last for up to 10 days at a time for 14 days aside. And what we have seen is that based on anecdotal evidence, whereby individuals that have done intensive monitoring using finger prick

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot